Co-occurring substance use and mental disorders among adults with opioid use disorder
•Co-occurring substance use and mental disorders are common among adults with OUD.•Receipt of both mental health and substance use disorder treatment is suboptimal.•Expansion of comprehensive care models for co-occurring disorders are needed. Co-occurring substance use and mental disorders among peo...
Saved in:
Published in | Drug and alcohol dependence Vol. 197; pp. 78 - 82 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Ireland
Elsevier B.V
01.04.2019
Elsevier Science Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | •Co-occurring substance use and mental disorders are common among adults with OUD.•Receipt of both mental health and substance use disorder treatment is suboptimal.•Expansion of comprehensive care models for co-occurring disorders are needed.
Co-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing these co-occurring conditions is critical for improving treatment and health outcomes. There is limited recent research on the prevalence of co-occurring disorders, demographic characteristics associated with co-occurring disorders, and receipt of mental health and substance use treatment services among those with OUD. This limits the development of targeted and resourced policies and clinical interventions.
Using 2015–2017 National Survey on Drug Use and Health data, prevalence of co-occurring substance use and mental disorders and receipt of mental health and substance use treatment services was estimated for adults aged 18–64 with OUD. Multivariable logistic regression assessed demographic and substance use characteristics associated with past-year mental illness (AMI) and serious mental illness (SMI) among adults with OUD as well as treatment receipt.
Among adults with OUD, prevalence of specific co-occurring substance use disorders ranged from 26.4% (95% CI:23.6%–29.4%) for alcohol to 10.6% (95% CI:8.6%–13.0%) for methamphetamine. Prevalence of AMI was 64.3% (95% CI:60.4%–67.9%) and SMI was 26.9% (95% CI:24.2%–29.8%). Receiving both mental health and substance use treatment services in the past year was reported by 24.5% (95% CI:21.5%–29.9%) of adults with OUD and AMI and 29.6% (95% CI:23.3%–36.7%) of adults with OUD and SMI.
Co-occurring substance use and mental disorders are common among adults with OUD. Expanding access to comprehensive service delivery models that address the substance use and mental health co-morbidities of this population is urgently needed. |
---|---|
AbstractList | •Co-occurring substance use and mental disorders are common among adults with OUD.•Receipt of both mental health and substance use disorder treatment is suboptimal.•Expansion of comprehensive care models for co-occurring disorders are needed.
Co-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing these co-occurring conditions is critical for improving treatment and health outcomes. There is limited recent research on the prevalence of co-occurring disorders, demographic characteristics associated with co-occurring disorders, and receipt of mental health and substance use treatment services among those with OUD. This limits the development of targeted and resourced policies and clinical interventions.
Using 2015–2017 National Survey on Drug Use and Health data, prevalence of co-occurring substance use and mental disorders and receipt of mental health and substance use treatment services was estimated for adults aged 18–64 with OUD. Multivariable logistic regression assessed demographic and substance use characteristics associated with past-year mental illness (AMI) and serious mental illness (SMI) among adults with OUD as well as treatment receipt.
Among adults with OUD, prevalence of specific co-occurring substance use disorders ranged from 26.4% (95% CI:23.6%–29.4%) for alcohol to 10.6% (95% CI:8.6%–13.0%) for methamphetamine. Prevalence of AMI was 64.3% (95% CI:60.4%–67.9%) and SMI was 26.9% (95% CI:24.2%–29.8%). Receiving both mental health and substance use treatment services in the past year was reported by 24.5% (95% CI:21.5%–29.9%) of adults with OUD and AMI and 29.6% (95% CI:23.3%–36.7%) of adults with OUD and SMI.
Co-occurring substance use and mental disorders are common among adults with OUD. Expanding access to comprehensive service delivery models that address the substance use and mental health co-morbidities of this population is urgently needed. Background: Co-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing these co-occurring conditions is critical for improving treatment and health outcomes. There is limited recent research on the prevalence of co-occurring disorders, demographic characteristics associated with co-occurring disorders, and receipt of mental health and substance use treatment services among those with OUD. This limits the development of targeted and resourced policies and clinical interventions. Methods: Using 2015–2017 National Survey on Drug Use and Health data, prevalence of co-occurring substance use and mental disorders and receipt of mental health and substance use treatment services was estimated for adults aged 18–64 with OUD. Multivariable logistic regression assessed demographic and substance use characteristics associated with past-year mental illness (AMI) and serious mental illness (SMI) among adults with OUD as well as treatment receipt. Results: Among adults with OUD, prevalence of specific co-occurring substance use disorders ranged from 26.4% (95% CI:23.6%–29.4%) for alcohol to 10.6% (95% CI:8.6%–13.0%) for methamphetamine. Prevalence of AMI was 64.3% (95% CI:60.4%–67.9%) and SMI was 26.9% (95% CI:24.2%–29.8%). Receiving both mental health and substance use treatment services in the past year was reported by 24.5% (95% CI:21.5%–29.9%) of adults with OUD and AMI and 29.6% (95% CI:23.3%–36.7%) of adults with OUD and SMI. Conclusions: Co-occurring substance use and mental disorders are common among adults with OUD. Expanding access to comprehensive service delivery models that address the substance use and mental health co-morbidities of this population is urgently needed. Co-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing these co-occurring conditions is critical for improving treatment and health outcomes. There is limited recent research on the prevalence of co-occurring disorders, demographic characteristics associated with co-occurring disorders, and receipt of mental health and substance use treatment services among those with OUD. This limits the development of targeted and resourced policies and clinical interventions.BACKGROUNDCo-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing these co-occurring conditions is critical for improving treatment and health outcomes. There is limited recent research on the prevalence of co-occurring disorders, demographic characteristics associated with co-occurring disorders, and receipt of mental health and substance use treatment services among those with OUD. This limits the development of targeted and resourced policies and clinical interventions.Using 2015-2017 National Survey on Drug Use and Health data, prevalence of co-occurring substance use and mental disorders and receipt of mental health and substance use treatment services was estimated for adults aged 18-64 with OUD. Multivariable logistic regression assessed demographic and substance use characteristics associated with past-year mental illness (AMI) and serious mental illness (SMI) among adults with OUD as well as treatment receipt.METHODSUsing 2015-2017 National Survey on Drug Use and Health data, prevalence of co-occurring substance use and mental disorders and receipt of mental health and substance use treatment services was estimated for adults aged 18-64 with OUD. Multivariable logistic regression assessed demographic and substance use characteristics associated with past-year mental illness (AMI) and serious mental illness (SMI) among adults with OUD as well as treatment receipt.Among adults with OUD, prevalence of specific co-occurring substance use disorders ranged from 26.4% (95% CI:23.6%-29.4%) for alcohol to 10.6% (95% CI:8.6%-13.0%) for methamphetamine. Prevalence of AMI was 64.3% (95% CI:60.4%-67.9%) and SMI was 26.9% (95% CI:24.2%-29.8%). Receiving both mental health and substance use treatment services in the past year was reported by 24.5% (95% CI:21.5%-29.9%) of adults with OUD and AMI and 29.6% (95% CI:23.3%-36.7%) of adults with OUD and SMI.RESULTSAmong adults with OUD, prevalence of specific co-occurring substance use disorders ranged from 26.4% (95% CI:23.6%-29.4%) for alcohol to 10.6% (95% CI:8.6%-13.0%) for methamphetamine. Prevalence of AMI was 64.3% (95% CI:60.4%-67.9%) and SMI was 26.9% (95% CI:24.2%-29.8%). Receiving both mental health and substance use treatment services in the past year was reported by 24.5% (95% CI:21.5%-29.9%) of adults with OUD and AMI and 29.6% (95% CI:23.3%-36.7%) of adults with OUD and SMI.Co-occurring substance use and mental disorders are common among adults with OUD. Expanding access to comprehensive service delivery models that address the substance use and mental health co-morbidities of this population is urgently needed.CONCLUSIONSCo-occurring substance use and mental disorders are common among adults with OUD. Expanding access to comprehensive service delivery models that address the substance use and mental health co-morbidities of this population is urgently needed. Co-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing these co-occurring conditions is critical for improving treatment and health outcomes. There is limited recent research on the prevalence of co-occurring disorders, demographic characteristics associated with co-occurring disorders, and receipt of mental health and substance use treatment services among those with OUD. This limits the development of targeted and resourced policies and clinical interventions. Using 2015-2017 National Survey on Drug Use and Health data, prevalence of co-occurring substance use and mental disorders and receipt of mental health and substance use treatment services was estimated for adults aged 18-64 with OUD. Multivariable logistic regression assessed demographic and substance use characteristics associated with past-year mental illness (AMI) and serious mental illness (SMI) among adults with OUD as well as treatment receipt. Among adults with OUD, prevalence of specific co-occurring substance use disorders ranged from 26.4% (95% CI:23.6%-29.4%) for alcohol to 10.6% (95% CI:8.6%-13.0%) for methamphetamine. Prevalence of AMI was 64.3% (95% CI:60.4%-67.9%) and SMI was 26.9% (95% CI:24.2%-29.8%). Receiving both mental health and substance use treatment services in the past year was reported by 24.5% (95% CI:21.5%-29.9%) of adults with OUD and AMI and 29.6% (95% CI:23.3%-36.7%) of adults with OUD and SMI. Co-occurring substance use and mental disorders are common among adults with OUD. Expanding access to comprehensive service delivery models that address the substance use and mental health co-morbidities of this population is urgently needed. |
Author | McCance-Katz, Elinore F. Jones, Christopher M. |
Author_xml | – sequence: 1 givenname: Christopher M. surname: Jones fullname: Jones, Christopher M. email: fjr0@cdc.gov organization: Centers for Disease Control and Prevention, 4770 Buford Highway, Atlanta, GA 30341, USA – sequence: 2 givenname: Elinore F. surname: McCance-Katz fullname: McCance-Katz, Elinore F. organization: Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30784952$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkU1vEzEQhi1URNPCX0CWuHDZxR8br_eCgIgCUiUu9Gy59mxx8NrBH0X997hNC1JO8cUa6ZnH43nP0EmIARDClPSUUPFu29tUb7Q3FnY9I1T2lPWEk2doReU4dYQM4gStCB9FJ0cqTtFZzlvSjpjIC3TKySiHac1W6GoTu2hMTcmFG5zrdS46GMA1A9bB4gVC0R5bl2OykDLWS2ygttWXjP-48hPHnYvOPnQ8YS_R81n7DK8e73N0dfH5x-Zrd_n9y7fNx8vODHJduoHKQVouNVAwQGbJNdOUjEQPrZhmwYZx5AyIHZloleGEw8RgttRqM8_8HL3de3cp_q6Qi1pcNuC9DhBrVqw9QNdD-2xD3xyg21hTaNMpxqhg60lI0ajXj1S9XsCqXXKLTnfqaWENkHvApJhzgvkfQom6z0Zt1f9s1H02ijLVsmmt7w9ajSu6uBhK0s4fI_i0F0Bb6a2DpLJx0NKyLoEpykZ3jOTDgcR4F5zR_hfcHaf4C2B6x0g |
CitedBy_id | crossref_primary_10_1111_1475_6773_14251 crossref_primary_10_1016_j_jsat_2022_108873 crossref_primary_10_1111_jmwh_13415 crossref_primary_10_1007_s11469_025_01449_7 crossref_primary_10_1080_15504263_2022_2052225 crossref_primary_10_1017_S0033291723003732 crossref_primary_10_1093_epirev_mxaa005 crossref_primary_10_1213_ANE_0000000000006280 crossref_primary_10_1016_j_ejogrb_2024_04_003 crossref_primary_10_61186_etiadpajohi_17_69_7 crossref_primary_10_1007_s11469_024_01315_y crossref_primary_10_1007_s11606_021_07249_8 crossref_primary_10_1016_j_drugpo_2023_104159 crossref_primary_10_1016_j_drugpo_2024_104434 crossref_primary_10_1177_0706743720912860 crossref_primary_10_1177_01939459241266736 crossref_primary_10_1186_s12889_021_12104_w crossref_primary_10_3389_fpsyt_2021_784229 crossref_primary_10_1155_2024_6299073 crossref_primary_10_1177_0310057X211066929 crossref_primary_10_1016_j_addbeh_2024_108104 crossref_primary_10_1007_s10461_020_03151_2 crossref_primary_10_1080_08897077_2020_1803179 crossref_primary_10_1111_ajad_13149 crossref_primary_10_1016_j_drugalcdep_2021_108661 crossref_primary_10_1016_j_drugalcdep_2020_108244 crossref_primary_10_1109_ACCESS_2022_3230596 crossref_primary_10_2105_AJPH_2021_306577 crossref_primary_10_1001_jamahealthforum_2023_1080 crossref_primary_10_1111_jrh_12851 crossref_primary_10_1177_11782218221103581 crossref_primary_10_1002_ejp_2114 crossref_primary_10_1080_10550887_2023_2247950 crossref_primary_10_1016_j_jsat_2021_108461 crossref_primary_10_1016_j_etdah_2024_100144 crossref_primary_10_3389_fpsyt_2022_850480 crossref_primary_10_1192_bjo_2023_81 crossref_primary_10_1080_10826084_2022_2079138 crossref_primary_10_1016_j_disamonth_2025_101853 crossref_primary_10_1016_j_drugalcdep_2023_111040 crossref_primary_10_1097_JAN_0000000000000470 crossref_primary_10_1016_j_drugalcdep_2021_109160 crossref_primary_10_1177_1357633X231190945 crossref_primary_10_54615_2231_7805_47358 crossref_primary_10_1177_09637214231162366 crossref_primary_10_1371_journal_pone_0306395 crossref_primary_10_1016_j_drugalcdep_2024_111409 crossref_primary_10_1136_bmjopen_2024_087560 crossref_primary_10_1016_j_drugalcdep_2020_108113 crossref_primary_10_1080_15332640_2023_2297392 crossref_primary_10_3928_02793695_20220510_01 crossref_primary_10_1016_j_drugalcdep_2021_108996 crossref_primary_10_1093_swr_svad015 crossref_primary_10_1177_08862605231179720 crossref_primary_10_1016_j_ygyno_2020_12_011 crossref_primary_10_1016_j_josat_2023_209023 crossref_primary_10_1111_jrh_12743 crossref_primary_10_1177_00333549231222479 crossref_primary_10_1111_adb_13282 crossref_primary_10_1186_s13722_024_00447_9 crossref_primary_10_1001_jamanetworkopen_2024_35478 crossref_primary_10_1186_s13722_023_00396_9 crossref_primary_10_1016_j_drugpo_2024_104570 crossref_primary_10_1007_s11920_022_01346_z crossref_primary_10_1016_j_drugalcdep_2023_111051 crossref_primary_10_1093_fampra_cmab171 crossref_primary_10_1111_bcp_16055 crossref_primary_10_1016_j_pmedr_2023_102494 crossref_primary_10_1007_s12024_024_00885_6 crossref_primary_10_1186_s12920_021_01100_z crossref_primary_10_1016_j_josat_2024_209428 crossref_primary_10_1016_j_healthpol_2023_104939 crossref_primary_10_1007_s00702_023_02720_8 crossref_primary_10_1080_24751979_2025_2473364 crossref_primary_10_1093_fampra_cmaf007 crossref_primary_10_1186_s12911_022_01869_8 crossref_primary_10_1017_S0033291721002300 crossref_primary_10_3389_fpsyg_2019_00577 crossref_primary_10_1080_07347324_2021_1972775 crossref_primary_10_1097_ADM_0000000000001140 crossref_primary_10_1080_13811118_2023_2220757 crossref_primary_10_1001_jamanetworkopen_2024_17545 crossref_primary_10_3389_fpubh_2023_1105681 crossref_primary_10_1016_j_jpsychires_2024_06_047 crossref_primary_10_1097_ADM_0000000000000961 crossref_primary_10_1016_j_drugalcdep_2021_108619 crossref_primary_10_1016_j_medleg_2023_100422 crossref_primary_10_1002_jac5_1331 crossref_primary_10_1016_j_drugpo_2023_104196 crossref_primary_10_1016_j_ypmed_2021_106817 crossref_primary_10_1080_08897077_2022_2095078 crossref_primary_10_1176_appi_prcp_20190051 crossref_primary_10_1016_j_cct_2021_106354 crossref_primary_10_1007_s44174_023_00150_4 crossref_primary_10_1016_j_cct_2024_107668 crossref_primary_10_1016_j_emc_2023_06_022 crossref_primary_10_1186_s12991_024_00517_x crossref_primary_10_1016_j_cct_2024_107782 crossref_primary_10_14475_jhpc_2024_27_1_45 crossref_primary_10_1097_ADM_0000000000001031 crossref_primary_10_3390_children9040524 crossref_primary_10_1016_j_jsat_2021_108309 crossref_primary_10_1016_j_dadr_2023_100195 crossref_primary_10_1097_ADM_0000000000001154 crossref_primary_10_1080_10509674_2023_2182866 crossref_primary_10_1186_s12888_023_05008_z crossref_primary_10_1111_1475_6773_13920 crossref_primary_10_2196_24561 crossref_primary_10_1016_j_ogc_2023_03_010 crossref_primary_10_1176_appi_ps_202000524 crossref_primary_10_1080_10550887_2023_2195777 crossref_primary_10_1177_1527154421989994 crossref_primary_10_1080_01612840_2020_1836540 crossref_primary_10_3389_fnsys_2022_1014768 crossref_primary_10_1186_s13722_022_00317_2 crossref_primary_10_1016_j_cct_2021_106325 crossref_primary_10_1038_s41398_021_01372_0 crossref_primary_10_30773_pi_2023_0328 crossref_primary_10_1177_26334895241301670 crossref_primary_10_1016_j_jpeds_2020_07_025 crossref_primary_10_2147_JPR_S457982 crossref_primary_10_1016_j_josat_2023_209217 crossref_primary_10_1007_s11469_022_00768_3 crossref_primary_10_1007_s10597_023_01117_x crossref_primary_10_1080_10826084_2023_2238301 crossref_primary_10_1097_ADM_0000000000000860 crossref_primary_10_1186_s12954_023_00906_7 crossref_primary_10_3389_fpsyt_2023_1255323 crossref_primary_10_1016_j_dadr_2024_100226 crossref_primary_10_1080_15332985_2021_1928586 crossref_primary_10_1016_j_drugalcdep_2019_02_033 crossref_primary_10_1044_2022_PERSP_21_00270 crossref_primary_10_1093_jbcr_irae168 crossref_primary_10_1371_journal_pone_0292674 crossref_primary_10_1007_s10597_023_01215_w crossref_primary_10_1176_appi_ajp_20230918 crossref_primary_10_1016_j_drugalcdep_2021_109013 crossref_primary_10_1080_14659891_2023_2293774 crossref_primary_10_1007_s40737_024_00398_z crossref_primary_10_1016_j_drugalcdep_2022_109551 crossref_primary_10_1080_14459795_2022_2044502 crossref_primary_10_1093_epirev_mxaa011 crossref_primary_10_1111_ajad_13526 crossref_primary_10_1080_10826084_2021_1981386 crossref_primary_10_3389_fpsyt_2021_750500 crossref_primary_10_61186_etiadpajohi_17_69_245 crossref_primary_10_1176_appi_ps_202000066 crossref_primary_10_1093_epirev_mxaa009 crossref_primary_10_30770_2572_1852_109_1_29 crossref_primary_10_1111_jrh_12799 crossref_primary_10_1080_15332985_2021_1929664 crossref_primary_10_1186_s13011_023_00538_x crossref_primary_10_1186_s12913_023_10136_z crossref_primary_10_1371_journal_pone_0281437 crossref_primary_10_1080_15566382_2023_2201961 crossref_primary_10_1111_nyas_14209 crossref_primary_10_1186_s13722_024_00467_5 crossref_primary_10_1016_j_jogn_2024_01_004 crossref_primary_10_1111_jnu_12879 crossref_primary_10_1177_00220426211006362 crossref_primary_10_1111_add_15392 crossref_primary_10_1111_dar_13634 crossref_primary_10_1016_j_drugalcdep_2021_108811 crossref_primary_10_1186_s12913_024_11820_4 crossref_primary_10_1001_jama_2024_11913 crossref_primary_10_1016_j_dadr_2024_100287 crossref_primary_10_1071_PY22269 crossref_primary_10_1177_0844562121996222 crossref_primary_10_1016_j_jclinane_2022_110674 crossref_primary_10_1016_j_xjep_2022_100542 crossref_primary_10_1177_1178221820981998 crossref_primary_10_1016_j_jadr_2023_100695 crossref_primary_10_1001_jamanetworkopen_2021_0061 crossref_primary_10_1186_s40352_022_00201_w crossref_primary_10_1001_jamanetworkopen_2023_15479 crossref_primary_10_1176_appi_ps_202000312 crossref_primary_10_1080_10826084_2021_1936051 crossref_primary_10_1186_s12916_024_03646_y crossref_primary_10_1016_j_abrep_2024_100573 crossref_primary_10_1111_papr_13427 crossref_primary_10_1001_jamanetworkopen_2024_27569 crossref_primary_10_1016_j_cct_2023_107248 crossref_primary_10_1016_j_drugalcdep_2020_108083 crossref_primary_10_1111_add_15845 crossref_primary_10_1016_j_drugalcdep_2021_109232 crossref_primary_10_1080_10826084_2023_2196574 crossref_primary_10_1111_dar_13885 crossref_primary_10_1111_acem_14758 crossref_primary_10_1016_j_josat_2023_209192 crossref_primary_10_1016_j_drugalcdep_2022_109734 crossref_primary_10_1177_1073110520979383 crossref_primary_10_2196_25575 crossref_primary_10_1093_haschl_qxae165 crossref_primary_10_1016_j_drugpo_2022_103853 crossref_primary_10_1177_00220221241249461 crossref_primary_10_2196_37351 crossref_primary_10_14423_SMJ_0000000000001709 crossref_primary_10_1111_1468_0009_12470 crossref_primary_10_1111_ajad_13431 crossref_primary_10_1177_26334895231152808 crossref_primary_10_1186_s12888_022_04500_2 crossref_primary_10_3389_fpsyt_2022_881821 crossref_primary_10_1016_j_mcna_2021_08_009 crossref_primary_10_1016_j_ypmed_2019_105771 crossref_primary_10_1007_s10461_024_04325_y crossref_primary_10_1097_ADM_0000000000000784 crossref_primary_10_7759_cureus_75629 crossref_primary_10_3390_ijerph192013481 crossref_primary_10_1016_j_drugpo_2021_103480 crossref_primary_10_1016_j_sapharm_2024_01_008 crossref_primary_10_1016_j_drugalcdep_2024_112447 crossref_primary_10_1038_s41390_021_01756_4 crossref_primary_10_1080_14659891_2023_2174908 crossref_primary_10_1016_j_ajem_2021_08_071 crossref_primary_10_1080_00952990_2024_2417820 crossref_primary_10_1016_j_drugalcdep_2023_110926 crossref_primary_10_1001_jamapsychiatry_2021_0247 crossref_primary_10_2340_17453674_2024_40708 crossref_primary_10_1007_s10943_025_02260_3 crossref_primary_10_1186_s12888_023_05436_x crossref_primary_10_1038_s41380_020_00949_3 crossref_primary_10_1016_j_jsat_2021_108283 crossref_primary_10_1038_s41380_024_02548_y crossref_primary_10_1016_j_abrep_2021_100382 crossref_primary_10_1002_jeab_741 crossref_primary_10_1007_s11126_022_09978_3 crossref_primary_10_1111_add_70008 crossref_primary_10_1016_j_jsat_2020_108155 crossref_primary_10_1080_10826084_2022_2064508 crossref_primary_10_1016_j_dadr_2022_100121 crossref_primary_10_1038_s44184_024_00086_7 crossref_primary_10_1111_add_15594 crossref_primary_10_1007_s11606_024_08718_6 crossref_primary_10_1007_s12671_024_02463_x crossref_primary_10_1016_j_josat_2024_209561 crossref_primary_10_9740_mhc_2023_12_268 crossref_primary_10_1016_j_josat_2025_209681 crossref_primary_10_1080_14659891_2022_2139304 crossref_primary_10_1177_27536386231171813 crossref_primary_10_1097_JXX_0000000000000801 crossref_primary_10_1080_14656566_2020_1732349 crossref_primary_10_1016_j_drugalcdep_2020_108162 crossref_primary_10_1080_20016689_2021_1966187 crossref_primary_10_2147_SAR_S412821 crossref_primary_10_1016_j_josat_2023_209269 crossref_primary_10_1016_j_amepre_2021_04_017 crossref_primary_10_1097_ADM_0000000000001420 crossref_primary_10_1016_j_pbb_2022_173495 crossref_primary_10_1111_jrh_70009 crossref_primary_10_1016_j_josat_2023_209273 crossref_primary_10_1080_14659891_2024_2323103 crossref_primary_10_1080_21645515_2022_2123201 crossref_primary_10_1186_s12954_024_01007_9 crossref_primary_10_1016_j_jad_2023_05_080 crossref_primary_10_1097_MD_0000000000023203 crossref_primary_10_1007_s10461_023_04211_z crossref_primary_10_1007_s10552_021_01513_2 crossref_primary_10_1016_j_ssmmh_2022_100151 crossref_primary_10_1186_s12954_023_00778_x crossref_primary_10_1080_15332985_2021_1975014 crossref_primary_10_1080_08897077_2021_1876202 crossref_primary_10_1108_JPMH_09_2023_0076 crossref_primary_10_1089_jpm_2024_0092 crossref_primary_10_1007_s40596_020_01264_3 crossref_primary_10_1016_j_cct_2023_107294 crossref_primary_10_1097_MLR_0000000000001851 crossref_primary_10_1136_bmjopen_2020_048353 crossref_primary_10_1080_24734306_2022_2110201 crossref_primary_10_3390_ijerph22030458 crossref_primary_10_1093_haschl_qxaf003 crossref_primary_10_1097_ADM_0000000000001434 crossref_primary_10_1016_j_jsat_2021_108495 crossref_primary_10_1001_jamahealthforum_2022_1757 crossref_primary_10_1080_15504263_2021_1979349 crossref_primary_10_1016_j_drugpo_2023_104211 crossref_primary_10_1186_s13722_021_00268_0 crossref_primary_10_1108_JCRPP_09_2020_0060 crossref_primary_10_1016_j_drugalcdep_2024_111286 crossref_primary_10_2147_IJGM_S295461 crossref_primary_10_1007_s10549_020_05998_4 crossref_primary_10_1186_s13722_022_00302_9 crossref_primary_10_15585_mmwr_mm7123a1 crossref_primary_10_3390_ijerph19116474 crossref_primary_10_1080_10550887_2024_2327728 crossref_primary_10_1097_MLR_0000000000001867 crossref_primary_10_1080_10826084_2023_2247071 crossref_primary_10_1097_PAF_0000000000000888 crossref_primary_10_1097_ADM_0000000000001200 crossref_primary_10_1093_pubmed_fdaf001 crossref_primary_10_1177_0033354919863430 crossref_primary_10_1016_j_josat_2023_209054 crossref_primary_10_1148_radiol_240514 crossref_primary_10_1002_emp2_12877 crossref_primary_10_1080_00952990_2021_1887202 crossref_primary_10_1192_j_eurpsy_2024_1797 crossref_primary_10_1016_j_jad_2024_07_078 |
Cites_doi | 10.1001/jama.2018.2844 10.1001/jama.2008.802 10.1097/ADM.0000000000000310 10.1016/j.ypmed.2018.01.019 10.1016/j.jsat.2008.06.006 10.15585/mmwr.mm6709e1 10.1007/s11606-012-2225-z 10.1300/J069v25n04_09 10.1001/jama.2011.370 |
ContentType | Journal Article |
Copyright | 2019 Published by Elsevier B.V. Copyright Elsevier Science Ltd. Apr 1, 2019 |
Copyright_xml | – notice: 2019 – notice: Published by Elsevier B.V. – notice: Copyright Elsevier Science Ltd. Apr 1, 2019 |
DBID | AAYXX CITATION NPM 7QJ 7TK 7U3 7U7 BHHNA C1K K9. NAPCQ 7X8 |
DOI | 10.1016/j.drugalcdep.2018.12.030 |
DatabaseName | CrossRef PubMed Applied Social Sciences Index & Abstracts (ASSIA) Neurosciences Abstracts Social Services Abstracts Toxicology Abstracts Sociological Abstracts Environmental Sciences and Pollution Management ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed Nursing & Allied Health Premium Toxicology Abstracts Sociological Abstracts ProQuest Health & Medical Complete (Alumni) Social Services Abstracts Applied Social Sciences Index and Abstracts (ASSIA) Neurosciences Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Nursing & Allied Health Premium MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Social Welfare & Social Work |
EISSN | 1879-0046 |
EndPage | 82 |
ExternalDocumentID | 30784952 10_1016_j_drugalcdep_2018_12_030 S0376871618305209 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 5GY 5RE 5VS 6PF 7-5 71M 8P~ 9JM 9JO AABNK AAEDT AAEDW AAFJI AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAWTL AAXKI AAXLA AAXUO ABBQC ABCQJ ABFNM ABIVO ABJNI ABLJU ABMAC ABMMH ABMZM ABZDS ACDAQ ACGFS ACHQT ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGUBO AGWIK AGYEJ AHHHB AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AOMHK APXCP AVARZ AXJTR BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W KOM M29 M39 M41 MO0 MOBAO N9A O-L O9- OAUVE OGGZJ OH0 OU- OZT P-8 P-9 P2P PC. PRBVW Q38 ROL RPZ SAE SCC SDF SDG SDP SEL SES SPCBC SSB SSH SSN SSO SSP SSZ T5K TN5 WH7 Z5R ~G- AACTN AADPK AAIAV AATCM ABLVK ABYKQ AFKWA AJOXV AKYCK AMFUW EFLBG LCYCR RIG .GJ 29G 53G AAQXK AAYWO AAYXX ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AFCTW AFJKZ AGQPQ AGRNS AIGII ASPBG AVWKF AZFZN CITATION FEDTE FGOYB G-2 HEG HMK HMO HVGLF HZ~ H~9 R2- SEW UAP WUQ XPP ZGI ZXP ZY4 NPM 7QJ 7TK 7U3 7U7 BHHNA C1K K9. NAPCQ 7X8 |
ID | FETCH-LOGICAL-c485t-41848d38ae1ece0f83a2a1070a40f89f6247732e0d726f62c303e92efd1dacff3 |
IEDL.DBID | .~1 |
ISSN | 0376-8716 1879-0046 |
IngestDate | Fri Jul 11 11:38:48 EDT 2025 Sat Jul 26 02:03:35 EDT 2025 Mon Jul 21 06:04:36 EDT 2025 Thu Apr 24 23:03:07 EDT 2025 Tue Jul 01 01:53:30 EDT 2025 Fri Feb 23 02:24:25 EST 2024 Tue Aug 26 20:29:13 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Serious mental illness Opioid overdose Opioid use disorder Co-occurring disorders Receipt of mental health and substance use treatment |
Language | English |
License | Published by Elsevier B.V. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c485t-41848d38ae1ece0f83a2a1070a40f89f6247732e0d726f62c303e92efd1dacff3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 30784952 |
PQID | 2216259686 |
PQPubID | 2033333 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_2184154784 proquest_journals_2216259686 pubmed_primary_30784952 crossref_primary_10_1016_j_drugalcdep_2018_12_030 crossref_citationtrail_10_1016_j_drugalcdep_2018_12_030 elsevier_sciencedirect_doi_10_1016_j_drugalcdep_2018_12_030 elsevier_clinicalkey_doi_10_1016_j_drugalcdep_2018_12_030 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2019-04-01 |
PublicationDateYYYYMMDD | 2019-04-01 |
PublicationDate_xml | – month: 04 year: 2019 text: 2019-04-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Ireland |
PublicationPlace_xml | – name: Ireland – name: Lausanne |
PublicationTitle | Drug and alcohol dependence |
PublicationTitleAlternate | Drug Alcohol Depend |
PublicationYear | 2019 |
Publisher | Elsevier B.V Elsevier Science Ltd |
Publisher_xml | – name: Elsevier B.V – name: Elsevier Science Ltd |
References | Hall, Logan, Toblin, Kaplan, Kraner, Bixler, Crosby, Paulozzi (bib0030) 2008; 300 Netherland, Botsko, Egan, Saxon, Cunningham, Finkelstein, Gourevitch, Renner, Sohler, Sullivan, Weiss, Fiellin, BHIVES Collaborative (bib0055) 2009; 36 American Psychiatric Association (bib0005) 1994 Brooklyn, Sigmon (bib0015) 2017; 11 The National Council (bib0070) 2017 Jones, McCance-Katz (bib0040) 2018 Johnson, Lanier, Merrill, Crook, Porucznik, Rolfs, Sauer (bib0035) 2013; 28 Campbell, Bahorik, VanVeldhuisen, Weisner, Rubinstein, Ray (bib0020) 2018; 110 Cunningham, Sohler, McCoy, Kunins (bib0025) 2006; 38 Substance Abuse and Mental Health Services Administration (bib0060) 2017 Jones, Einstein, Compton (bib0045) 2018; 319 Vivolo-Kantor, Seth, Gladden, Mattson, Baldwin, Kite-Powell, Coletta (bib0075) 2018; 67 Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (bib0065) 2018 Kissin, McLeod, Sonnefeld, Stanton (bib0050) 2006; 25 Bohnert, Valenstein, Bair, Ganoczy, McCarthy, Ilgen, Blow (bib0010) 2011; 305 Hall (10.1016/j.drugalcdep.2018.12.030_bib0030) 2008; 300 Jones (10.1016/j.drugalcdep.2018.12.030_bib0040) 2018 Vivolo-Kantor (10.1016/j.drugalcdep.2018.12.030_bib0075) 2018; 67 Bohnert (10.1016/j.drugalcdep.2018.12.030_bib0010) 2011; 305 Cunningham (10.1016/j.drugalcdep.2018.12.030_bib0025) 2006; 38 Johnson (10.1016/j.drugalcdep.2018.12.030_bib0035) 2013; 28 The National Council (10.1016/j.drugalcdep.2018.12.030_bib0070) 2017 Brooklyn (10.1016/j.drugalcdep.2018.12.030_bib0015) 2017; 11 Campbell (10.1016/j.drugalcdep.2018.12.030_bib0020) 2018; 110 Substance Abuse and Mental Health Services Administration (10.1016/j.drugalcdep.2018.12.030_bib0060) 2017 Kissin (10.1016/j.drugalcdep.2018.12.030_bib0050) 2006; 25 Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (10.1016/j.drugalcdep.2018.12.030_bib0065) 2018 Netherland (10.1016/j.drugalcdep.2018.12.030_bib0055) 2009; 36 American Psychiatric Association (10.1016/j.drugalcdep.2018.12.030_bib0005) 1994 Jones (10.1016/j.drugalcdep.2018.12.030_bib0045) 2018; 319 |
References_xml | – volume: 11 start-page: 286 year: 2017 end-page: 292 ident: bib0015 article-title: Vermont Hub-and-Spoke model of care for opioid use disorder: development, implementation, and impact publication-title: J. Addict. Med. – year: 2018 ident: bib0040 article-title: Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder publication-title: Addiction – year: 2017 ident: bib0070 article-title: Certified Community Behavioral Health Clinics: Fact Sheet – volume: 36 start-page: 244 year: 2009 end-page: 251 ident: bib0055 article-title: Factors affecting willingness to provide buprenorphine treatment publication-title: J. Subst. Abuse Treat. – volume: 110 start-page: 31 year: 2018 end-page: 37 ident: bib0020 article-title: Use of a prescription opioid registry to examine opioid misuse and overdose in an integrated health system publication-title: Prev. Med. – volume: 319 start-page: 1819 year: 2018 end-page: 1821 ident: bib0045 article-title: Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010–2016 publication-title: JAMA – volume: 67 start-page: 279 year: 2018 end-page: 285 ident: bib0075 article-title: Vital signs: trends in emergency department visits for suspected opioid overdose – United States, July 2016–September 2017 publication-title: MMWR Morb. Mortal. Wkly. Rep. – volume: 300 start-page: 2613 year: 2008 end-page: 2620 ident: bib0030 article-title: Patterns of abuse among unintentional pharmaceutical overdose fatalities publication-title: JAMA – year: 2017 ident: bib0060 article-title: Results from the 2016 National Survey on Drug Use and Health – year: 2018 ident: bib0065 article-title: 2017 National Survey on Drug Use and Health: Methodological Summary and Definitions – volume: 305 start-page: 1315 year: 2011 end-page: 1321 ident: bib0010 article-title: Association between opioid prescribing patterns and opioid overdose-related deaths publication-title: JAMA – volume: 38 start-page: 336 year: 2006 end-page: 340 ident: bib0025 article-title: Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital publication-title: Fam. Med. – year: 1994 ident: bib0005 article-title: Diagnostic and Statistical Manual of Mental Disorders – volume: 28 start-page: 522 year: 2013 end-page: 529 ident: bib0035 article-title: Unintentional prescription opioid-related overdose deaths: description of decedents by next of kin or best contact, Utah, 2008–2009 publication-title: J. Gen. Intern. Med. – volume: 25 start-page: 91 year: 2006 end-page: 103 ident: bib0050 article-title: Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence publication-title: J. Addict. Dis. – volume: 38 start-page: 336 year: 2006 ident: 10.1016/j.drugalcdep.2018.12.030_bib0025 article-title: Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital publication-title: Fam. Med. – volume: 319 start-page: 1819 year: 2018 ident: 10.1016/j.drugalcdep.2018.12.030_bib0045 article-title: Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010–2016 publication-title: JAMA doi: 10.1001/jama.2018.2844 – volume: 300 start-page: 2613 year: 2008 ident: 10.1016/j.drugalcdep.2018.12.030_bib0030 article-title: Patterns of abuse among unintentional pharmaceutical overdose fatalities publication-title: JAMA doi: 10.1001/jama.2008.802 – volume: 11 start-page: 286 year: 2017 ident: 10.1016/j.drugalcdep.2018.12.030_bib0015 article-title: Vermont Hub-and-Spoke model of care for opioid use disorder: development, implementation, and impact publication-title: J. Addict. Med. doi: 10.1097/ADM.0000000000000310 – volume: 110 start-page: 31 year: 2018 ident: 10.1016/j.drugalcdep.2018.12.030_bib0020 article-title: Use of a prescription opioid registry to examine opioid misuse and overdose in an integrated health system publication-title: Prev. Med. doi: 10.1016/j.ypmed.2018.01.019 – volume: 36 start-page: 244 year: 2009 ident: 10.1016/j.drugalcdep.2018.12.030_bib0055 article-title: Factors affecting willingness to provide buprenorphine treatment publication-title: J. Subst. Abuse Treat. doi: 10.1016/j.jsat.2008.06.006 – year: 2017 ident: 10.1016/j.drugalcdep.2018.12.030_bib0060 – year: 2018 ident: 10.1016/j.drugalcdep.2018.12.030_bib0065 – volume: 67 start-page: 279 year: 2018 ident: 10.1016/j.drugalcdep.2018.12.030_bib0075 article-title: Vital signs: trends in emergency department visits for suspected opioid overdose – United States, July 2016–September 2017 publication-title: MMWR Morb. Mortal. Wkly. Rep. doi: 10.15585/mmwr.mm6709e1 – issue: September year: 2018 ident: 10.1016/j.drugalcdep.2018.12.030_bib0040 article-title: Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder publication-title: Addiction – volume: 28 start-page: 522 year: 2013 ident: 10.1016/j.drugalcdep.2018.12.030_bib0035 article-title: Unintentional prescription opioid-related overdose deaths: description of decedents by next of kin or best contact, Utah, 2008–2009 publication-title: J. Gen. Intern. Med. doi: 10.1007/s11606-012-2225-z – volume: 25 start-page: 91 year: 2006 ident: 10.1016/j.drugalcdep.2018.12.030_bib0050 article-title: Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence publication-title: J. Addict. Dis. doi: 10.1300/J069v25n04_09 – year: 2017 ident: 10.1016/j.drugalcdep.2018.12.030_bib0070 – volume: 305 start-page: 1315 year: 2011 ident: 10.1016/j.drugalcdep.2018.12.030_bib0010 article-title: Association between opioid prescribing patterns and opioid overdose-related deaths publication-title: JAMA doi: 10.1001/jama.2011.370 – year: 1994 ident: 10.1016/j.drugalcdep.2018.12.030_bib0005 |
SSID | ssj0000690 |
Score | 2.6611838 |
Snippet | •Co-occurring substance use and mental disorders are common among adults with OUD.•Receipt of both mental health and substance use disorder treatment is... Co-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing these... Background: Co-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 78 |
SubjectTerms | Adults Alcohols Co-occurring disorders Comorbidity Demographics Demography Drug abuse Drug addiction Drug use Health information Health status Medical treatment Mental disorders Mental health Mental health care Mental health services Methamphetamine Morbidity Mortality Narcotics Opioid overdose Opioid use disorder Opioids Polls & surveys Receipt of mental health and substance use treatment Serious mental illness Substance abuse treatment Substance use Substance use disorder |
Title | Co-occurring substance use and mental disorders among adults with opioid use disorder |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0376871618305209 https://dx.doi.org/10.1016/j.drugalcdep.2018.12.030 https://www.ncbi.nlm.nih.gov/pubmed/30784952 https://www.proquest.com/docview/2216259686 https://www.proquest.com/docview/2184154784 |
Volume | 197 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dixMxEA_H-eKL-G21HhHEt9jdbJpk8ekoHlXxXrR4byGbD6keu6Xbvt7ffjObbFVQKPiY7AxkZyaTSTLzCyGvtZe14q5muvEFE1E5ZlWtmPQQP5fexibije7nS7lciY9X86sTshhrYTCtMvv-5NMHb517Zlmas816PftSwNzAcB-MckjmwAp2odDK396Uv3njdM4CxAypczZPyvHy2z34YecDIleWejgYxHzovy9R_wpBh6Xo4j65l2NIep6G-YCchPYhmaZCW_otXEe7DfQNHTu67c9HZLXoWOccHvi132kP7mKH-qb7PlDbepow_qnPYJw9HV4hogM8R0_xtJZ2m3W39gPHSPaYrC7ef10sWX5SgTmh5zsmYEOnfaVtKIMLRdSV5RZ2gIUV0Kij5EKpiofCKy6h5WCFCzUP0YPeXIzVE3Ladm14RmiMQWpRVbLhDmKuee2aJnoEOxSFbmQzIWqUonEZbxyfvbg2Y2LZD_NL_gblb0puQP4TUh44Nwlz4wieelSUGWtKwQsaWBiO4H134P3D9o7kno52YfL87w3nJW4spZYT8urwGWYuXsfYNnR7oAFdlAinJibkabKnw--C59WwdeXP_2toL8hdaNUp0WhKTnfbfXgJMdSuORsmyRm5c_7h0_LyFj0eHSk |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-N7gFeEIyvjjI8CfFmNXFSxxFPU8XUsa0vrGJvluOPqTAlVdP-_zvHTgEJpEp7jO2TnLP9uzv7_DPAJ2F4WTBdUlGZhOau0FQVZUG5Qf85NcpVzp_oXs_5bJF_u53cHsC0vwvj0yoj9gdM79A6loyjNser5XL8PcG14d19nJRdMscTOPTsVJMBHJ5dXM7mfwBy2GrB9tQLxISekOZl1luEYm2sJ69MRbc36FOi_22l_ueFdtbo_AU8j24kOQs9fQkHtj6CUbhrS37Ye6fWlnwmfUGz_vUKFtOGNlr7Pb_6jrSIGBs_5GTbWqJqQwLNPzGRj7Ml3UNEpGPoaInfsCXNatksTSfRN3sNi_OvN9MZja8qUJ2LyYbmGNMJkwllU6tt4kSmmMIgMFE5fpSOs7woMmYTUzCOXxqNnC2ZdQaHTjuXvYFB3dT2HRDnLBd5lvGKaXS7JqWuKmc832GeiIpXQyh6LUodKcf9yxf3ss8t-yl_6196_cuUSdT_ENKd5CrQbuwhU_YDJftrpQiEEm3DHrJfdrJ_Tb89pUf9vJARAlrJWOpjSy74EE531bh4_YmMqm2zxTY4FqlnVMuH8DbMp93vIvgKjF7Z8aO69hGezm6ur-TVxfzyPTzDmjLkHY1gsFlv7Qd0qTbVSVwyD-yxH9o |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Co-occurring+substance+use+and+mental+disorders+among+adults+with+opioid+use+disorder&rft.jtitle=Drug+and+alcohol+dependence&rft.au=Jones%2C+Christopher+M&rft.au=McCance-Katz%2C+Elinore+F&rft.date=2019-04-01&rft.pub=Elsevier+Science+Ltd&rft.issn=0376-8716&rft.eissn=1879-0046&rft.volume=197&rft.spage=78&rft_id=info:doi/10.1016%2Fj.drugalcdep.2018.12.030&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0376-8716&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0376-8716&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0376-8716&client=summon |